[Screening program on novel drug resistance mutations of subtype B' in human immunodeficiency virus type 1 in China]. 2011

Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Science, Beijing 100071, China.

OBJECTIVE To screen the level of novel drug resistance mutations in subtype B' in China. METHODS 451 pol sequences collected from the previous study, which including 354 AIDS patients who had received antiretroviral treatment (ART) and 97 the untreated patients. Entire protease gene (codons 1 - 99) and full-length reverse transcriptase gene (codons 1 - 560) were included. Variation of mutations between the treated and the untreated patients with consensus/ancestral sequences were compared and the mutations with higher frequencies in the treated patients than in the untreated patients were screened before submitting the mutations to the Stanford HIV Drug Resistance Database (SHDB) (http: //hivdb.stanford.edu/). Relation between the mutations and resistance preliminarily was then analyzed, according to the information including SHDB. RESULTS Frequencies of 7 mutations at 6 positions, D123E, V292I, K366R, T369A, T369V, A371V and I375V, 2 at DNA polymerase domain and 5 at connection domain of reverse transcriptase (RT) were higher in the treated patients than in the untreated patients. The information of 7 mutations including the SHDB showed that 7 mutations were major variants at corresponding positions, and theirs frequencies were higher in the treated patients using some drugs, than in the untreated patients. CONCLUSIONS 7 mutations being screened from the China subtype B were possibly associated with the resistance, which called for the construction of mutated viruses by site-directed mutagenesis to identify their effects on the susceptivity of different drugs.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015751 Genes, pol DNA sequences that form the coding region for retroviral enzymes including reverse transcriptase, protease, and endonuclease/integrase. "pol" is short for polymerase, the enzyme class of reverse transcriptase. pol Genes,pol Gene,Gene, pol
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
December 2017, The Journal of infectious diseases,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
May 2006, The Journal of general virology,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
May 2009, Journal of virology,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
May 1994, The Journal of general virology,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
June 2006, Antimicrobial agents and chemotherapy,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
August 2004, Antimicrobial agents and chemotherapy,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
March 1996, Annals of the Academy of Medicine, Singapore,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
November 2022, Chinese medical journal,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
May 2003, Journal of molecular evolution,
Han-Ping Li, and Wei Guo, and Yong-Jian Liu, and Zuo-Yi Bao, and Lin Li, and Dao-Min Zhuang, and Si-Yang Liu, and Zheng Wang, and Xiao-Lin Wang, and Jing-Yun Li
December 2007, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!